These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14567371)

  • 21. Trends in antihypertensive drug advertising, 1985-1996.
    Wang TJ; Ausiello JC; Stafford RS
    Circulation; 1999 Apr; 99(15):2055-7. PubMed ID: 10209012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace?
    Hernandez AF; Harrington RA
    CMAJ; 2008 May; 178(10):1316-9. PubMed ID: 18458264
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.
    Kvan E; Reikvam A;
    Eur J Clin Pharmacol; 2004 May; 60(3):205-10. PubMed ID: 15034703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.
    Duetz MS; Schneeweiss S; Maclure M; Abel T; Glynn RJ; Soumerai SB
    Clin Ther; 2003 Jan; 25(1):273-84. PubMed ID: 12637126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II and trials of cardiovascular outcomes.
    Sleight P
    Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National use of postmenopausal hormone therapy: annual trends and response to recent evidence.
    Hersh AL; Stefanick ML; Stafford RS
    JAMA; 2004 Jan; 291(1):47-53. PubMed ID: 14709575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
    Gerstein HC
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.
    Grover SA; Coupal L; Lowensteyn I
    Am J Cardiovasc Drugs; 2007; 7(6):441-8. PubMed ID: 18076211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators.
    McGavock H; Webb CH; Johnston GD; Milligan E
    BMJ; 1993 Oct; 307(6912):1118-20. PubMed ID: 7902744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of new evidence on prescription patterns.
    Calvo CB; Rubinstein A
    J Am Board Fam Pract; 2002; 15(6):457-62. PubMed ID: 12463291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].
    Pocanić D
    Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.